About toripalima b
PD-1 blocking monoclonal antibody
Used for
- Advanced nasopharyngeal cancer, together with chemotherapy
- Recurrent or metastatic nasopharyngeal cancer after platinum chemotherapy
Usual adult dose
Intravenous infusion: 3 mg/kg every two weeks when used alone; combination treatment uses a different schedule.
Common side effects
- Tiredness
- Rash and itching
- Diarrhea
- Reduced thyroid function
Important warnings
- Immune reactions can seriously damage organs, sometimes after treatment ends
- Severe infusion reactions can occur
- Requires monitoring of liver, kidney, and thyroid function
- May cause complications following stem cell transplantation
Pregnancy
Can harm an unborn baby. Effective contraception is required during treatment and for four months after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment or for four months after the last dose.
Interactions
- Immunosuppressants may reduce effectiveness; corticosteroids may treat immune-related side effects
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.